menu
    • menu

    Company profile for OrphAI Therapeutics

    NEW Drugs in Dev: 5
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OrphAI Therapeutics is dedicated to the identification and development of treatments for rare orphan conditions. Employing diverse methods, we actively seek promising assets to enhance our pipeline. Our ongoing clinical stage drug candidates are designed to address various orphan disorders, spanning amyotrophic lateral sclerosis, pulmonary hypertension, bronchiolitis obliterans post-lung transplant, pulmonary sarcoidosis, Ewin...
    OrphAI Therapeutics is dedicated to the identification and development of treatments for rare orphan conditions. Employing diverse methods, we actively seek promising assets to enhance our pipeline. Our ongoing clinical stage drug candidates are designed to address various orphan disorders, spanning amyotrophic lateral sclerosis, pulmonary hypertension, bronchiolitis obliterans post-lung transplant, pulmonary sarcoidosis, Ewing Sarcoma, Rhabdoid Tumor, and SWI/SNF mutated or dysregulated cancers. Our commitment is to advance therapeutic solutions for these rare conditions with unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OrphAI TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Guilford, CT 06437
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.orphai-therapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orphaitherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OrphAI Therapeutics Presents Phase 2a LAM-001 Data at ATS 2026
    OrphAI Therapeutics Presents Phase 2a LAM-001 Data at ATS 2026

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3222002/0/en/Orphai-Therapeutics-Phase-2a-LAM-001-Study-Selected-for-Oral-Presentation-at-the-American-Thoracic-Society-ATS-2026-International-Conference.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    OrphAI Therapeutics Appoints Dr. Aaron Waxman to Board
    OrphAI Therapeutics Appoints Dr. Aaron Waxman to Board

    19 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/19/3028953/0/en/OrphAI-Therapeutics-Announces-Appointment-of-Dr-Aaron-Waxman-to-Board-of-Directors.html

    GLOBENEWSWIRE
    19 Feb 2025
    Share Share
    OrphAI Therapeutics receives Orphan Drug Designation for AIT-101
    OrphAI Therapeutics receives Orphan Drug Designation for AIT-101

    15 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/15/2830145/0/en/OrphAI-Therapeutics-receives-Orphan-Drug-Designation-for-AIT-101-as-a-treatment-for-amyotrophic-lateral-sclerosis-in-the-European-Union.html

    GLOBENEWSWIRE
    15 Feb 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search